First-year treatment costs among new initiators of topical prostaglandin analogs

Jordana K. Schmier, David W. Covert, Alan L. Robin

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: To estimate first-year costs among new initiators of topical prostaglandin analogs in a managed care population. Research design and methods: We developed a model to estimate first-year direct medical costs. We derived treatment patterns from a claims database analysis. Published studies were used to estimate visit-related resource use. Costs were obtained from standard sources. Results: The database analysis identified 9,063 patients meeting study criteria, 41% (n = 3,672) of whom remained on their initial prostaglandin therapy for 12 months after initiation. Adjunctive intraocular pressure lowering therapy was needed in 20.7%, 16.5%, 13.9%, and 8.9% of bimatoprost, latanoprost, travoprost, and BAK-free travoprost patients, respectively. Median numbers of days to the first prescription filled for adjunctive therapy (if required) were 69.5, 67.0, 123.0, and 158.5 for patients initiating on bimatoprost, latanoprost, travoprost, and BAK-free travoprost. Total estimated first-year costs were $1,457, $1,360, $1,278, and $1,307 for patients initiating therapy with bimatoprost, latanoprost, travoprost, and BAK-free travoprost. Findings were consistent through sensitivity analysis. Conclusions: A BAK-free prostaglandin analog may permit longer duration of monotherapy and be associated with lower first-year direct medical costs. Use of a claims database and the selection of new initiators of prostaglandin analogs limit projecting findings to all glaucoma patients.

Original languageEnglish (US)
Pages (from-to)637-644
Number of pages8
JournalClinical Ophthalmology
Volume3
Issue number1
DOIs
StatePublished - 2009

Keywords

  • Combination
  • Costs and cost analysis
  • Drug therapy
  • Glaucoma
  • Prostaglandin analogs

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint

Dive into the research topics of 'First-year treatment costs among new initiators of topical prostaglandin analogs'. Together they form a unique fingerprint.

Cite this